Immix Biopharma, Inc. (IMMX)
14.31
+0.24
(+1.71%)
USD |
NASDAQ |
Aug 27, 16:00
14.10
-0.21
(-1.47%)
After-Hours: 05:10
Immix Biopharma Total Liabilities (Quarterly) : 10.19M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 10.19M |
| March 31, 2026 | 11.45M |
| December 31, 2025 | 11.04M |
| September 30, 2025 | 11.82M |
| June 30, 2025 | 10.98M |
| March 31, 2025 | 10.30M |
| December 31, 2024 | 9.697M |
| September 30, 2024 | 7.591M |
| June 30, 2024 | 4.945M |
| March 31, 2024 | 6.716M |
| Date | Value |
|---|---|
| December 31, 2023 | 3.722M |
| September 30, 2023 | 2.826M |
| June 30, 2023 | 2.396M |
| March 31, 2023 | 1.473M |
| December 31, 2022 | 1.748M |
| September 30, 2022 | 0.6465M |
| June 30, 2022 | 0.9772M |
| March 31, 2022 | 0.3651M |
| December 31, 2021 | 0.202M |
| September 30, 2021 | 6.691M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Savara, Inc. | 48.48M |
| SELLAS Life Sciences Group, Inc. | 7.726M |
| Atossa Therapeutics, Inc. | 5.451M |
| Marker Therapeutics, Inc. | 2.42M |
| Krystal Biotech, Inc. | 141.52M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 239.11M |
| Shareholders Equity (Quarterly) | 228.92M |
| Debt to Equity Ratio | 0.0044 |
| Current Ratio | 25.13 |
| Net Debt Paydown Yield | 0.00% |